Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Concurrent loss of TP53 and CDKN2A with tetraploidy predicts richter transformation and poor prognosis in chronic lymphocytic leukemia

Blood (2025) 146 (Supplement 1): 2133.

https://doi.org/10.1182/blood-2025-2133

Published: 2025

Journal Articles

Pretargeted glycoengineered NK cell (PG-NK) therapy: A universal off-the-shelf platform redefining targeted cell therapy strategies in lymphoma

Supriya Chakraborty, Rajeswaran Mani, Lawrence Druhan, Bethany Wildeman, Margaret Templeton, Samon Benrashid, Sara Seegers, David Foureau, Venkata Udumula, Andrew Wang, Steven Park

Blood (2025) 146 (Supplement 1): 2358.

https://doi.org/10.1182/blood-2025-2358

Published: 2025

Journal Articles

Targeting BTKi-resistant CLL using the dual irreversible/reversible 4th generation BTK inhibitor rocbrutinib

Blood (2025) 146 (Supplement 1): 1532.

https://doi.org/10.1182/blood-2025-1532

Published: 2025

Journal Articles

Dysregulation of NF-kb and p73 signal axes in chronic lymphocytic leukemia with gain-of-function mutated p53

Samon Benrashid, Britten Gordon, Andrew Mitchell, Alexander He, Tzung-Huei Lai, Shrilekha Misra, Shanmugapriya Thangavadivel, Kerry Rogers, Deepa Sampath, Jennifer Woyach

Blood (2025) 146 (Supplement 1): 7405.

https://doi.org/10.1182/blood-2025-7405

Published: 2025

Journal Articles

Genome-Wide CRISPR/Cas9 Knockout Screen Reveals Novel LP-168 (Rocbrutinib) Combinations Targeting BCL-2 Protein Members for Chronic Lymphocytic Leukemia

Blood (2024) 144 (Supplement 1): 3587.

https://doi.org/10.1182/blood-2024-203522

Published: 2024

Journal Articles

Targeting Inflammation in Tet2 Mutant Clonal Hematopoiesis Via Inhibition of Brd4 Demonstrates Activity in Both Murine and Human Models

Alexander R. Marr, Madeline Halpin, Dominique L. Corbin, Britten K. Gordon, Samon Benrashid, Ethan C. Whipp, Jean Truxall, Olivia Cahn, Bethany L. Mundy-Bosse, Julia Cooper, Marina Beltrami Moreira, James S. Blachly, Uma Borate, Jennifer A. Woyach, Rosa Lapalombella, Nicole R. Grieselhuber

Blood (2024) 144 (Supplement 1): 2661.

https://doi.org/10.1182/blood-2024-203526

Published: 2024

Journal Articles

Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib

Jennifer A. Woyach, Daniel Jones, Wojciech Jurczak, Tadeusz Robak, Árpád Illés, Arnon P. Kater, Paolo Ghia, John C. Byrd, John F. Seymour, Susan Long, Nehad Mohamed, Samon Benrashid, Tzung-Huei Lai, Gary De Jesus, Richard Lai, Gerjan de Bruin, Simon Rule, Veerendra Munugalavadla

Blood (2024) 144 (10): 1061–1068.

https://doi.org/10.1182/blood.2023023659

Published: 2024

Includes: Supplemental data

Journal Articles

Single-Cell RNA-Seq Analysis Reveals Distinct Tumor and Immunosuppressive T Cell Phenotypes in CLL Patients Treated with Ibrutinib

Shanmugapriya Thangavadivel, Shrilekha Misra, Samon Benrashid, Britten Gordon, Alexander He, Tzung-Huei Lai, Kerry A Rogers, Seema A Bhat, Adam S Kittai, John C. Byrd, James S. Blachly, Jennifer A. Woyach, Bradley Wayne Blaser

Blood (2023) 142 (Supplement 1): 3262.

https://doi.org/10.1182/blood-2023-186604

Published: 2023

Journal Articles

Brd4 Inhibition Abrogates Inflammation and Self-Renewal in a Murine Model of Tet2 Mutated Clonal Hematopoiesis

Alexander Marr, Madeline Halpin, Dominique Corbin, Britten Gordon, Samon Benrashid, Ethan C. Whipp, Mehdi Gharghabi, Jean Truxall, Olivia Cahn, Kristin L Koenig, Karilyn T. Larkin, Jennifer A. Woyach, Rosa Lapalombella, Nicole R. Grieselhuber

Blood (2023) 142 (Supplement 1): 4070.

https://doi.org/10.1182/blood-2023-179237

Published: 2023

Journal Articles

The PKC-β Inhibitor MS-553 Displays Preclinical Efficacy in BTK Inhibitor Resistant Chronic Lymphocytic Leukemia

Blood (2023) 142 (Supplement 1): 2260.

https://doi.org/10.1182/blood-2023-182024

Published: 2023

Journal Articles

Targeting Covalent and Non-Covalent Btki-Resistant CLL Using the Dual Irreversible/Reversible 4 th Generation BTK Inhibitor LP-168

Blood (2023) 142 (Supplement 1): 416.

https://doi.org/10.1182/blood-2023-178259

Published: 2023

Journal Articles

T Cell Dysfunction and Exhaustion in Patients with CLL: The Impact of Long Term Ibrutinib Treatment

Shanmugapriya Thangavadivel, Charlene Mao, Meixiao Long, Shrilekha Misra, Samon Benrashid, Britten Gordon, Alexander He, Tzung-Huei Lai, Kerry A Rogers, Seema A Bhat, Adam S Kittai, John C. Byrd, Jennifer A. Woyach

Blood (2023) 142 (Supplement 1): 4631.

https://doi.org/10.1182/blood-2023-189755

Published: 2023

Journal Articles

The Novel Multitarget Small-Molecule Inhibitor SRX3177 Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma

Dhananjaya Pal, Cody C. McHale, Samon Benrashid, Poornima Gourabathini, Krishnaiah Maddeboina, Kendra R. Vann, Rajeswaran Mani, Tatiana Kutateladze, Peter Martin, Maurizio Di Liberto, Selina Chen-Kiang, Steven I. Park, Donald L. Durden

Blood (2021) 138 (Supplement 1): 2262.

https://doi.org/10.1182/blood-2021-154253

Published: 2021

Journal Articles

Aurora Kinase Inhibition Overcomes Primary Venetoclax Failure and Leads to Synthetic Lethality in BCL2-Positive Lymphomas Via Upregulation of P53/P21/BAX Axis

Rajeswaran Mani, Samon Benrashid, Sarah E Teague, Scott C Jaros, Hsih-Te Yang, Lawrence J Druhan, David M Foureau, Nury M Steuerwald, Nilanjan Ghosh, Edward A. Copelan, Donald L. Durden, Belinda Avalos, Steven I. Park

Blood (2021) 138 (Supplement 1): 682.

https://doi.org/10.1182/blood-2021-146064

Published: 2021

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

Concurrent loss of TP53 and CDKN2A with tetraploidy predicts richter transformation and poor prognosis in chronic lymphocytic leukemia

Pretargeted glycoengineered NK cell (PG-NK) therapy: A universal off-the-shelf platform redefining targeted cell therapy strategies in lymphoma

Targeting BTKi-resistant CLL using the dual irreversible/reversible 4th generation BTK inhibitor rocbrutinib

Dysregulation of NF-kb and p73 signal axes in chronic lymphocytic leukemia with gain-of-function mutated p53

Genome-Wide CRISPR/Cas9 Knockout Screen Reveals Novel LP-168 (Rocbrutinib) Combinations Targeting BCL-2 Protein Members for Chronic Lymphocytic Leukemia

Targeting Inflammation in Tet2 Mutant Clonal Hematopoiesis Via Inhibition of Brd4 Demonstrates Activity in Both Murine and Human Models

Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib

Single-Cell RNA-Seq Analysis Reveals Distinct Tumor and Immunosuppressive T Cell Phenotypes in CLL Patients Treated with Ibrutinib

Brd4 Inhibition Abrogates Inflammation and Self-Renewal in a Murine Model of Tet2 Mutated Clonal Hematopoiesis

The PKC-β Inhibitor MS-553 Displays Preclinical Efficacy in BTK Inhibitor Resistant Chronic Lymphocytic Leukemia

Targeting Covalent and Non-Covalent Btki-Resistant CLL Using the Dual Irreversible/Reversible 4 th Generation BTK Inhibitor LP-168

T Cell Dysfunction and Exhaustion in Patients with CLL: The Impact of Long Term Ibrutinib Treatment

The Novel Multitarget Small-Molecule Inhibitor SRX3177 Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma

Aurora Kinase Inhibition Overcomes Primary Venetoclax Failure and Leads to Synthetic Lethality in BCL2-Positive Lymphomas Via Upregulation of P53/P21/BAX Axis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only